Cardiovascular Diseases

Introduction

The cardiovascular health activities are in response to the growing burden of these diseases due to the social, demographic, epidemiologic and health care transitions that have led to cardiovascular diseases being the number one cause of death in the country.

The activities are dedicated to:

  • Providing a platform for cardiovascular health research that is relevant to resource-limited settings
  • Focusing on key individual determinants (tobacco, diet, physical activity and psychological factors) as well as underlying social determinants (‘causes of causes’)
  • Providing a robust training environment that will foster a new generation of scholars engaged in cardiovascular research
  • Enhancing the translation and dissemination of research findings among vulnerable populations
  • Achieving a reputation for excellence in cardiovascular health research

Sl No. Title Authors Journal Name Publication Year
31 Association of Nut Intake With Risk Factors, Cardiovascular Disease, and Mortality in 16 Countries From 5 Continents: Analysis From the Prospective Urban and Rural Epidemiology (PURE) Study de Souza RJ, Dehghan M, Mente A, Bangdiwala SI, Ahmed SH, Alhabib KF, Altuntas Y, Basiak-Rasa?a A, Dagenais GR, Diaz R, Amma LI, Kelishadi R, Khatib R, Lear SA, Lopez-Jaramillo P, Mohan V, Poirier P, Rangarajan S, Rosengren A, Ismail R, Swaminathan S, Wentzel-Viljoen E, Yeates K, Yusuf R, Teo KK, Anand SS, Yusuf S, PURE study investigators Am J Clin Nutr 2020
32 In Patients With Stable Coronary Heart Disease, Low-Density Lipoprotein-Cholesterol Levels < 70 mg/dL and Glycosylated Hemoglobin A1c < 7% Are Associated With Lower Major Cardiovascular Events White HD, Stewart RAH, Dalby AJ, Stebbins A, Cannon CP, Budaj A, Linhart A, Pais P, Diaz R, Steg PG, Krug-Gourley S, Granger CB, Hochman JS, Koenig W, Harrington RA, Held C, Wallentin L, STABILITY Investigators Am Heart J 2020
33 Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- And Middle-Income Countries Chandrashekhar Y, Alexander T, Mullasari A, Kumbhani DJ, Alam S, Alexanderson E, Bachani D, Badenhorst JCW, Baliga R, Bax JJ, Bhatt DL, Bossone E, Botelho R, Chakraborthy RN, Chazal RA, Dhaliwal RS, Gamra H, Harikrishnan SP, Jeilan M, Kettles DI, Mehta S, Mohanan PP, Naber CK, Naik N, Ntsekhe M, Otieno HA, Pais P, Piñeiro DJ, Prabhakaran D, Reddy KS, Redha M, Roy A, Sharma M, Shor R, Snyders FA, Tan JWC, Valentine CM, Wilson BH, Yusuf S, Narula J Circulation 2020
34 Assessment of Dulaglutide Safety in Older Patient Populations in REWIND Konig M, Gerstein HC, Lakshmanan MC, Xavier D, Allen S, Cushman WC, Leiter LA, Raubenheimer PJ Journal of the Endocrine Society 2020
35 Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study Anjana RM, Mohan V, Rangarajan S, Gerstein HC, Venkatesan U, Sheridan P, Dagenais GR, Lear SA, Teo K, Karsidag K, Alhabib KF, Yusoff K, Ismail N, Mony PK, Lopez-Jaramillo P, Chifamba J, Palileo-Villanueva LM, Iqbal R, Yusufali A, Kruger IM, Rosengren A, Bahonar A, Zatonska K, Yeates K, Gupta R, Li W, Hu L, Rahman MO, Lakshmi PVM, Iype T, Avezum A, Diaz R, Lanas F, Yusuf S Diabetes Care 2020
36 Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L, Lakshmanan M, Mellbin L, Probstfield J, Riddle MC, Shaw JE, *Pais P*, et al.. Eur Heart J 2020
37 Urinary Sodium and Potassium, and Risk of Ischaemic and Haemorrhagic Stroke (INTERSTROKE): a case-control study Judge C, O'Donnell MJ, Hankey GJ, Rangarajan S, Chin SL, Rao-Melacini P, Ferguson J, Smyth A, Xavier D, Lisheng L, Zhang H, Lopez-Jaramillo P, Damasceno A, Langhorne P, Rosengren A, Dans AL, Elsayed A, Avezum A, Mondo C, Ryglewicz D, Czlonkowska A, Pogosova N, Weimar C, Diaz R, Yusoff K, Yusufali A, Oguz A, Wang X, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Oveisgharan S, Hussain FA, Yusuf S Am J Hypertens 2020
38 Polypill with or without Aspirin in Persons without Cardiovascular Disease Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, López-Jaramillo P, Yusoff K, Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F, Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P; International Polycap Study 3 Investigators N Engl J Med 2020
39 Association of dairy consumption with metabolic syndrome, hypertension and diabetes in 147 812 individuals from 21 countries Balaji Bhavadharini 1, Mahshid Dehghan 1, Andrew Mente 2 3, Sumathy Rangarajan 1, Patrick Sheridan 1, Viswanathan Mohan 4 5, Romaina Iqbal 6, Rajeev Gupta 7, Scott Lear 8, Edelweiss Wentzel-Viljoen 9, Alvaro Avezum 10, Patricio Lopez-Jaramillo 11, Prem Mony 12, Ravi Prasad Varma 13, Rajesh Kumar 14, Jephat Chifamba 15, Khalid F Alhabib 16, Noushin Mohammadifard 17, Aytekin Oguz 18, Fernando Lanas 19, Dorota Rozanska 20, Kristina Bengtsson Bostrom 21, Khalid Yusoff 22, Lungiswa P Tsolkile 23, Antonio Dans 24, Afzalhussein Yusufali 25, Andres Orlandini 26, Paul Poirier 27, Rasha Khatib 28, Bo Hu 29, Li Wei 30, Lu Yin 29, Ai Deeraili 31, Karen Yeates 32, Rita Yusuf 33, Noorhassim Ismail 34, Dariush Mozaffarian 35, Koon Teo 1 3 36, Sonia S Anand 1 3 36, Salim Yusuf 1 3 36 BMJ Open Diabetes Res Care 2020
40 Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study Salim Yusuf 1, Philip Joseph 2, Sumathy Rangarajan 2, Shofiqul Islam 2, Andrew Mente 2, Perry Hystad 3, Michael Brauer 4, Vellappillil Raman Kutty 5, Rajeev Gupta 6, Andreas Wielgosz 7, Khalid F AlHabib 8, Antonio Dans 9, Patricio Lopez-Jaramillo 10, Alvaro Avezum 11, Fernando Lanas 12, Aytekin Oguz 13, Iolanthe M Kruger 14, Rafael Diaz 15, Khalid Yusoff 16, Prem Mony 17, Jephat Chifamba 18, Karen Yeates 19, Roya Kelishadi 20, Afzalhussein Yusufali 21, Rasha Khatib 22, Omar Rahman 23, Katarzyna Zatonska 24, Romaina Iqbal 25, Li Wei 26, Hu Bo 26, Annika Rosengren 27, Manmeet Kaur 28, Viswanathan Mohan 29, Scott A Lear 30, Koon K Teo 2, Darryl Leong 2, Martin O'Donnell 31, Martin McKee 32, Gilles Dagenais 33 Lancet 2020
41 Situational analysis of practice patterns and challenges in cardiovascular disease management: A qualitative study Farah Naaz Fathima, Twinkle Agrawal, Padmini Nidhin, *Denis Xavier* Int. J of Non communicable Diseases 2020
42 Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation Anthony P Carnicelli, Sana M Al-Khatib, *Denis Xavier*, Frederik Dalgaard, Peter D Merrill, Daniel M Wojdyla, Basil S Lewis, Michael Hanna, John H Alexander, Renato D Lopes, Lars Wallentin, Christopher B Granger. Heart 2020
43 Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries Chow CK, Nguyen TN, Marschner S, Diaz R, Rahman O, Avezum A, Lear SA, Teo K, Yeates KE, Lanas F, Li W, Hu B, Lopez-Jaramillo P, Gupta R, Kumar R, Mony PK, Bahonar A, Yusoff K, Khatib R, Kazmi K, Dans AL, Zatonska K, Alhabib KF, Kruger IM, Rosengren A, Gulec S, Yusufali A, Chifamba J, Rangarajan S, McKee M, Yusuf S; PURE Study BMJ Glob Health 2020
44 Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial Szarek M, Steg PG, DiCenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Jukema JW, Pordy R, Roe MT, Sourdille T, White HD, Xavier D, Zeiher AM, Schwartz GG Circ Cardiovasc Qual Outcomes 2019
45 Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, Gersh BJ, Hanna M, Horowitz J, Hylek EM, Xavier D, Verheugt FWA, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. J Thromb Thrombolysis 2019